Gennao Bio
Mr. Duke is an accomplished biotech executive with more than 20 years of global commercial, operational and clinical development experience at several leading rare disease and immuno-oncology companies. Mr. Duke previously served as chief operating officer of Gennao since its inception in 2020 and helped establish and led key corporate functions, including program management, manufacturing, legal, business operations, human resources, and information technology. Before Gennao, Mr. Duke led operations and the commercial team in Japan for Amicus Therapeutics, after previously serving as the company’s vice president of global commercial operations. He also was chief operating officer for Advaxis, Inc., and executive director of international commercial operations for NPS Pharma. Earlier in his career, Mr. Duke held clinical and scientific positions at Merck & Co. and The Schering-Plough Corporation. He received an MBA from the Wharton School at the University of Pennsylvania, as well as an M.P.H. and a B.S. in Chemical Engineering from Rutgers University.
This person is not in any offices
Gennao Bio
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.